Mersana Therapeutics has entered into an option agreement with GSK for the codevelopment and commercialization of XMT-2056, an Immunosynthen antibody-drug conjugate (ADC) that targets a novel epitope of HER2.

Innovation Pharmaceuticals' brilacidin, a defensin-mimetic drug candidate exhibiting broad-spectrum antiviral properties, is to be evaluated for its treatment potential against the monkeypox virus.

Genmab and BioNTech have expanded their global strategic collaboration to develop and commercialize novel immunotherapies for the treatment of cancer. Under the expansion, Genmab and BioNTech will jointly work to research, develop and commercialize novel monospecific antibody candidates for various cancer indications.

BriaCell Therapeutics has secured an exclusive license from University of Maryland, Baltimore County (UMBC) to develop and commercialize soluble CD80 (sCD80) as a biologic agent for the treatment of cancer.

Xenetic Biosciences and VolitionRx have entered into a research and development collaboration to develop neutrophil extracellular traps (NETs)-targeted, adoptive cell therapies for the treatment of cancer.

Caris Life Sciences and Xencor have entered into a multi-year strategic option and license agreement to research, develop and commercialize XmAb bispecific antibodies directed against novel targets for the treatment of patients with cancer.

Ipsen and Marengo Therapeutics have entered into a strategic partnership to advance two of Marengo's preclinical STAR (Selective T Cell Activation Repertoire) platform-generated candidates into the clinic.